Certara (CERT) Q1 2026 Earnings Call Transcript

Certara reported Q1 revenue of $106.9 million, up 1% year over year, with software revenue rising 7% to $49.7 million and software bookings up 20% to $48.7 million. However, services revenue fell 4%, adjusted EBITDA declined to $31.7 million from $34.8 million, and GAAP net loss widened to $8.8 million, offsetting the software strength. Management kept full-year 2026 guidance at $395 million to $405 million revenue and 30%-32% adjusted EBITDA margin while outlining an AI platform push, a reorganization into MID3 and ACE, and completed divestiture of the regulatory/medical writing unit.

Analysis

CERT is trying to re-rate itself from a lumpy services compounder into a higher-visibility software/platform story, but the market will need proof that the reorg improves conversion rather than simply reallocates revenue between buckets. The divestiture removes a structurally noisy business, which should mechanically lift mix quality and make reported growth look cleaner in 2H and into 2027, but it also strips away an earnings contributor that helped cushion weak quarters. The key second-order effect is that software now has to carry both growth and operating leverage; if bookings stay ahead of revenue, margin expansion can accelerate quickly, but any slip in enterprise sales execution will be more visible than before.

The AI narrative is more interesting as a distribution and workflow wedge than as an immediate monetization engine. CERT’s edge is not generic model-building; it is regulatory trust, validated data, and embedded workflows that make its tools hard to replace and even harder for customers to self-build. That makes NVDA less of a headline partnership than an inference that CERT is moving toward accelerated compute-enabled simulation, where the likely near-term payoff is shorter cycle times and larger seat penetration rather than a pricing step-up.

The biggest contrarian point is that management is implicitly admitting the legacy commercial model was under-optimized, so the current acceleration is partly self-help. That means the stock can work if Q2/Q3 show services stabilization and software retention holds above 105%, but if the back-half ramp is mostly comp relief and backlog catch-up, the multiple expansion case will stall. The setup is attractive for a tactical long only if investors believe the organizational churn is front-loaded and 2027 becomes the first clean year of the new mix.

Key Decisions for Investors

• Long CERT on a 3-6 month horizon into expected 2H margin inflection; use size discipline because the thesis depends on execution, not just strategic optionality.
• Buy CERT Jan-2027 calls or call spreads to express the view that AI/platform monetization is a 2027 event; downside is defined if the platform takes longer to convert.
• Pair trade: long CERT / short a lower-quality healthcare services name with weaker software mix and no AI workflow moat; the relative trade should benefit if investors reward revenue visibility over pure growth.
• Avoid chasing NVDA on this specific print; the partnership is strategically supportive but not meaningfully incremental to NVDA near-term fundamentals.
• Set a catalyst alert around the next two quarters: if software NRR stays >=105% and services bookings stop deteriorating, add to CERT; if not, fade rallies above the post-earnings move.